Cholangiocarcinoma, also known as bile duct cancer, is a rare disease. It's a devastating condition incurable at the point ...

A Lancet study projects a surge in liver cancer cases, reaching 1.52 million by 2050, primarily driven by obesity. Deaths are ...

“There are a lot of treatment options depending on how bad your liver disease is, how many cancers in the liver you have, how ...

The albumin-bilirubin (ALBI) score can independently predict prognosis in post-surgical patients with distal cholangiocarcinoma (dCCA), a form of cholangiocarcinoma (CCA), according to results ...

In terms of consensus rating, Incyte is in the middle compared to its peers. Incyte has the highest revenue growth among its peers. Incyte also has the highest gross profit. However, Incyte has the ...

Adjuvant camrelizumab and concurrent chemoradiotherapy can improve outcomes in patients with gallbladder cancer and extrahepatic cholangiocarcinoma.

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

Australia's Pharmaceutical Benefits Scheme will have its second overhaul in three years with new laws to lower the maximum ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended regulators approve Servier's IDH1/2 inhibitor Voranigo (vorasidenib) as a treatment for ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising ...

本研究利用20K人类蛋白质组芯片技术，成功鉴定出DCDC2作为肝内胆管癌（ICC）的新型肿瘤相关抗原（TAA），并揭示了其在肿瘤进展和免疫逃逸中的关键作用。通过抗体芯片的广谱筛选，研究发现ICC患者血清中抗DCDC2自身抗体水平显著升高，表明其作为潜 ...